J-GLOBAL ID:201101025911685638   Update date: Apr. 19, 2023


サトウ ショウ | SATO Sho
Research theme for competitive and other funds  (1):
  • 2020 - 抗レトロウィルス薬のドラッグリパーパシングによるLINE1発現子宮体癌の治療戦略
Papers (10):
  • Ogasawara A, Shintani D, Sato S, Hasegawa K. Adjuvant chemotherapy in patients with uterine carcinosarcoma: a review of clinical outcomes and considerations. Expert Opinion on Orphan Drugs. 2021. 9. 11-12
  • Yuji Ikeda, Sho Sato, Akira Yabuno, Daisuke Shintani, Aiko Ogasawara, Maiko Miwa, Makda Zewde, Takashi Miyamoto, Keiichi Fujiwara, Yusuke Nakamura, et al. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo. J Gynecol Oncol. 2020. 31. 6. e93
  • Daisuke Shintani, Taro Hihara, Aiko Ogasawara, Sho Sato, Akira Yabuno, Kenji Tai, Keiichi Fujiwara, Keisuke Watanabe, ◎Kosei Hasegawa. Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer. Int J Gynecol Cancer. 2020. 30. 9. 1340-1346
  • Aiko Ogasawara, Sho Sato, ◎Kosei Hasegawa. Current and future strategies for treatment of ovarian clear cell carcinoma. Journal of Obstetrics and Gynaecology Research. 2020. 46. 9. 1678-1689
  • Hirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda, Shogo Yamamoto, Kayo Asada, Takahiro Karasaki, Akira Yabuno, Akira Nishijima, Takahide Nejo, Yukari Kobayashi, et al. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer . 2020. 8. 1. e000375
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page